Biosimilar Pipeline Report for 2H 2026

IPD Analytics has released its Biosimilar Pipeline Report for 2H 2026.

As of June 15, 2026, the FDA has approved six new biosimilars this year, including the first biosimilars to tumor necrosis factor (TNF) inhibitors Simponi and Simponi Aria. With a growing pipeline of near-term approvals and launches, lower-cost biosimilars continue to play a critical role in controlling drug spend as biologics remain a leading driver of rising healthcare costs.

The report also highlights recent FDA guidance changes that may streamline biosimilar development, potentially cutting pharmacokinetic study costs by up to 50% and lowering market entry barriers for manufacturers.

To stay current as the biosimilar market evolved, IPD subscribers can use this report alongside IPD’s Clinical Development Tracker within the Payer & Provider Insights platform, which delivers up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.